ELV
Elevance HealthBNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-17
Current thesis
The Q2 beat, higher FY26 guidance, stronger cash-flow outlook, Carelon revenue growth, and targeted cost-management investments improve the recovery case. Management also reiterated a path to at least 12% adjusted EPS growth in 2027 [#SEC-8K-2026-07-15].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +1.7.
What can break
Elevated medical-cost trends in government businesses could pressure benefit margins.
Momentum
47
Value
67
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $430.00 · Bull $480.00 · Bear $320.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $446.67
Why
Momentum47 · Δ7d -26.7
Value67 · Δ7d +1.7
Sentiment60 · Δ7d +17.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
47
26% active weight
Current posture
7d trendSoftening
Δ7d
-26.7
Δ21d
-35.3
Value
67
39% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
+1.4
Sentiment
60
34% active weight
Current posture
7d trendImproving
Δ7d
+17.0
Δ21d
+13.3
Why this grade
Composite grade B. Momentum 47.1 / Value 66.6 / Sentiment 59.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$81.03B
Beta
0.50
Shares Out
217.16M
P/E (TTM)
14.9
P/S (TTM)
0.41
P/FCF (TTM)
36.79
Rev YoY
+2.6%
EPS YoY
-16.7%
Gross Margin
-
Op Margin
+4.4%
Net Debt
$23.22B
Current Ratio
1.48
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology